Aclaris Therapeutics Inc (NASDAQ: ACRS) closed the day trading at $1.19 down -1.65% from the previous closing price of $1.21. In other words, the price has decreased by -$0.0200 from its previous closing price. On the day, 718773 shares were traded.
Ratios:
For a better understanding of ACRS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 23 when Monahan Joseph sold 6,000 shares for $5.08 per share. The transaction valued at 30,460 led to the insider holds 129,724 shares of the business.
Balthaser Kevin bought 9,490 shares of ACRS for $74,971 on Sep 06. The Chief Financial Officer now owns 15,461 shares after completing the transaction at $7.90 per share. On Aug 28, another insider, Loerop James, who serves as the Chief Business Officer of the company, bought 14,705 shares for $6.80 each. As a result, the insider paid 99,959 and bolstered with 21,688 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 84.30M and an Enterprise Value of -18.45M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.93 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at -0.59 whereas that against EBITDA is 0.18.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $13.09, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 1.1320, while the 200-Day Moving Average is calculated to be 5.5530.
Shares Statistics:
Over the past 3-months, ACRS traded about 2.48M shares per day on average, while over the past 10 days, ACRS traded about 1.14M shares per day. A total of 66.69M shares are outstanding, with a floating share count of 64.47M. Insiders hold about 8.99% of the company’s shares, while institutions hold 89.41% stake in the company. Shares short for ACRS as of Jan 31, 2024 were 6.33M with a Short Ratio of 2.55, compared to 5.79M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.94% and a Short% of Float of 10.30%.
Earnings Estimates
Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.43, while EPS last year was -$0.41. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.24 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$1.41 and -$1.71 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.17, with 10 analysts recommending between -$0.75 and -$2.13.
Revenue Estimates
8 analysts predict $3.36M in revenue for the current quarter. It ranges from a high estimate of $9.63M to a low estimate of $700k. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $7.75M, an estimated decrease of -56.70% from the year-ago figure.
A total of 9 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $28.7M, while the lowest revenue estimate was $14.38M, resulting in an average revenue estimate of $18.34M. In the same quarter a year ago, actual revenue was $29.75M, down -38.40% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $11.74M in the next fiscal year. The high estimate is $37.1M and the low estimate is $2.82M. The average revenue growth estimate for next year is down -36.00% from the average revenue estimate for this year.
